<table border="1"><tr><th>Drug</th><td><ul><li>Actinomycin D, bleomycin, docetaxel, temozolomide, dacarbazine, Aldesleukin | ( | d | ) |, procarbazine, lomustine | ( | en | ) | hydroxyurea, dabrafenib, lambrolizumab, vemurafenib, cobimetinib | ( | en | ) |, nivolumab, bevacizumab, trametinib | ( | en | ) |, paclitaxel, ipilimumab, peginterferon alfa-2b and sargramostim | ( | en | )</li></ul></td></tr><tr><th>Specialty</th><td><ul><li>Oncology</li></ul></td></tr><tr><th>CISP-2</th><td><ul><li>S77</li></ul></td></tr><tr><th>CIM-10</th><td><ul><li> C43</li></ul></td></tr><tr><th>CIM-9</th><td><ul><li>172.9</li></ul></td></tr><tr><th>ICD-O</th><td><ul><li> M8720/3</li></ul></td></tr><tr><th>OMIM</th><td><ul><li>155600</li></ul></td></tr><tr><th>DiseasesDB</th><td><ul><li>7947</li></ul></td></tr><tr><th>MedlinePlus</th><td><ul><li>000850</li></ul></td></tr><tr><th>eMedical</th><td><ul><li>1100753 | med/1386ent/27 | plastic/456</li></ul></td></tr><tr><th>MeSH</th><td><ul><li> D008545</li></ul></td></tr></table>